Featured Research

from universities, journals, and other organizations

X-Rays Yield Mechanism Of Alzheimer's Drug

Date:
February 25, 2003
Source:
Weizmann Institute
Summary:
A team of Weizmann scientists has gained new insight into the effects of a newly approved drug, rivastigmine, in treating Alzheimer’s disease, a debilitating brain disease causing memory loss in around 10% of the elderly.

A team of Weizmann scientists has gained new insight into the effects of a newly approved drug, rivastigmine, in treating Alzheimer’s disease, a debilitating brain disease causing memory loss in around 10% of the elderly. The study was published in the American Chemical Society journal Biochemistry.

Related Articles


“The results were surprising,” says Prof. Joel Sussman, of the Structural Biology Department. “They show that we can safely treat Alzheimer’s disease with much lower quantities of rivastigmine, thus minimizing unwanted adverse effects.”

The drug, currently sold as ExelonTM, helps slow memory loss of Alzheimer patients. However, its mechanism of action at the molecular level had not been studied prior to this research, which was conducted by Prof. Sussman, Prof. Israel Silman of the Neurobiology Department, and Ph.D. student Pazit Bar-on.

Alzheimer’s disease involves deterioration of nerve cells releasing a substance called acetylcholine, which carries messages between brain cells. The lack of acetylcholine in Alzheimer’s patients is compounded by the action of an enzyme called acetylcholinesterase (AChE), which rapidly breaks down acetylcholine. The desired effect of Alzheimer drugs like rivastigmine is to inhibit AChE long enough to adequately raise the levels of acetylcholine.

“We wanted to see how long it takes AChEs to return to normal, or become ‘reactivated,’ after inhibition by the drug,” says Prof. Silman. Testing rivastigmine on various types of AChE (extracted from an electric ray, the fruit fly and humans), the team was surprised to find that inhibition was almost irreversible, with little reactivation over a period of days.

To explain this at the molecular level, the scientists took snapshots of rivastigmine bound to AChE by projecting X-rays onto crystals of rivastigmine combined with AChE, and observing the X-rays’ diffraction patterns. They then built a molecular map showing the spatial arrangement of all the atoms of AChE and rivastigmine.

Using these maps, the scientists found why the inhibition of AChE by the drug is nearly irreversible: after binding to AChE, rivastigmine breaks in two and moves some of AChE’s atoms, making it difficult for it to return to an active state.

The maps provide important information for designing novel chemicals that might fight Alzheimer’s more effectively and with less side effects.

###

Prof. Joel Sussman’s research is supported by the Jean and Jula Goldwurm Memorial Foundation, Charles A. Dana Foundation, Irwin Green Research Fund in Brain Development, the Joseph and Ceil Mazer Center for Structural Biology, Helen & Milton A. Kimmelman Center for Bio-molecular Structure & Assembly. Prof. Sussman is the incumbent of the Morton and Gladys Pickman Chair in Structural Biology.


Story Source:

The above story is based on materials provided by Weizmann Institute. Note: Materials may be edited for content and length.


Cite This Page:

Weizmann Institute. "X-Rays Yield Mechanism Of Alzheimer's Drug." ScienceDaily. ScienceDaily, 25 February 2003. <www.sciencedaily.com/releases/2003/02/030225065751.htm>.
Weizmann Institute. (2003, February 25). X-Rays Yield Mechanism Of Alzheimer's Drug. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2003/02/030225065751.htm
Weizmann Institute. "X-Rays Yield Mechanism Of Alzheimer's Drug." ScienceDaily. www.sciencedaily.com/releases/2003/02/030225065751.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com
Doctors Often Give In To Vaccine-Wary Parents

Doctors Often Give In To Vaccine-Wary Parents

Newsy (Mar. 2, 2015) A new survey published in the journal Pediatrics found many doctors are giving in to parents&apos; requests to delay vaccinating their children. Video provided by Newsy
Powered by NewsLook.com
The Best Ways To Celebrate National Nutrition Month

The Best Ways To Celebrate National Nutrition Month

Buzz60 (Mar. 2, 2015) Just when your New Year&apos;s Resolution is losing steam, March comes with fresh inspiration. TC Newman (@PurpleTCNewman) has some tips to incorporate into your lifestyle during National Nutrition Month. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins